China Medicine Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHME research report →
Companywww.cmc621.com/cmc/index.php
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.
- CEO
- Senshan Yang
- IPO
- 2006
- Employees
- 281
- HQ
- Guangzhou, CN
Price Chart
Valuation
- Market Cap
- $474.24K
- P/E
- 0.18
- P/S
- 0.01
- P/B
- 0.01
- EV/EBITDA
- 0.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 29.32%
- Op Margin
- 18.94%
- Net Margin
- 2.65%
- ROE
- 3.91%
- ROIC
- 5.61%
Growth & Income
- Revenue
- $64.75M · 20.70%
- Net Income
- $1.72M · -81.18%
- EPS
- $0.11 · -81.67%
- Op Income
- $12.27M
- FCF YoY
- 761.00%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 11.80
- Avg Volume
- 1.86K
Get TickerSpark's AI analysis on CHME
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CHME Coverage
We haven't published any research on CHME yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHME Report →